Acetyl-Carnitine and Improved Survival

Doses used in studies

g/day: 3 (median 3, IQR 3–3) — 1 study

Time to effect

Median: 24.3 months · IQR 24.3 months–24.3 months · Range 24.3 months–24.3 months — Reported in 1 of 1 study

1 of 1 paper

Retrospective observational study on the use of acetyl-L-carnitine in ALS.

2023-06-28
Observational · n = 45
Journal of neurology 270(11)
- Serena Sassi
- Elisa Bianchi
- Luca Diamanti
- Danilo Tornabene
- Elisabetta Sette
- Doriana Medici
- Sabrina Matà
- Deborah Leccese
- Martina Sperti
- Ilaria Martinelli
- Andrea Ghezzi
- Jessica Mandrioli
- Valentina Virginia Iuzzolino
- Raffaele Dubbioso
- Francesca Trojsi
- Carla Passaniti
- Giulia D'Alvano
- Massimiliano Filosto
- Alessandro Padovani
- Letizia Mazzini
- Fabiola De Marchi
- Lucia Zinno
- Andi Nuredini
- Paolo Bongioanni
- Cristina Dolciotti
- Elena Canali
- Giulia Toschi
- Antonio Petrucci
- Alessia Perna
- Vittorio Riso
- Maurizio Inghilleri
- Laura Libonati
- Chiara Cambieri
- Elisabetta Pupillo

PubMed: 37378756
DOI: 10.1007/s00415-023-11844-6

5 Insights on

Improved Survival

Moderate evidence
Clinical

ALCAR 1.5 g/day vs not treated: 22 not treated subjects (48.9%) were still alive at 24 months after baseline, compared to 32 (71.1%) treated subjects (adj. OR 0.27, 95% CI 0.10-0.71).

Effect: Beneficial
Effect size: Large
Significant: Yes
Dose: 1.5 g/day